The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for ...

Healthcare company Viatris has been certified as a Great Place to Work® in both Australia and New Zealand, marking the first ...

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...